Cycle ID: 1

Hypotheses generated: H1, H2, H3, H4

---

**Hypothesis ID:** H1

**Hypothesis title:**  
Hypoxic MK methionine accumulation drives AMD1-mediated polyamine metabolism, shifting perivascular immune/stromal tone and contributing to medial thickening and vascular stiffening.

**PI instruction addressed:**  
Metabolomics-driven, direction-level: differential metabolite -> KEGG pathway-neighbor enzyme -> MK expression/differential -> broad downstream axis -> vascular remodeling. Uses user metabolomics (MK-sorted, PH vs control), Seurat scRNA-seq, and public dataset validation.

**Core directional hypothesis:**  
Increased methionine in PH-MKs drives AMD1-dependent polyamine (SAM, spermidine/spermine) production, which alters the pulmonary perivascular microenvironment—likely via immune modulation or direct vascular-wall signalling—augmenting hypoxia-induced medial thickening and vascular stiffness.

**Direction-level reasoning summary:**  
- **Data anchor:** MK-sorted metabolomics shows methionine up in PH vs control (log2FC 3.26); AMD1 is pathway-neighbor gene in Cysteine/methionine metabolism and Methionine salvage. Seurat: AMD1 expressed in 31.4 % of MKs (enrichment log2 1.35) and significantly upregulated in PH-MKs (log2FC 1.77, p=6.55e‑06).  
- **Biological interpretation:** Hypoxic MKs accumulate methionine, a precursor for SAM and polyamines. AMD1 catalyzes SAM decarboxylation, committing flux towards polyamine synthesis (spermidine/spermine). The strong MK enrichment and PH-up shift indicate hypoxia-induced metabolic reprogramming centred on polyamine metabolism.  
- **MK-linked pathway logic:** AMD1 is a rate-limiting enzyme for polyamine biosynthesis. Literature links mTORC1-AMD1 to polyamine metabolism in cancer, and polyamines (e.g., spermidine) regulate T‑cell differentiation and vascular cell proliferation. This positions MK AMD1 as a plausible metabolic rheostat in the hypoxic lung.  
- **Candidate downstream axes:** Polyamines secreted by MKs or released via extracellular vesicles could act (i) **immune-mediated** (e.g., promote Th17-like T‑cell or macrophage polarization), (ii) **direct vascular-wall** (stimulate SMC proliferation/fibroblast activation), or (iii) **EV/stromal** (alter matrix cross-linking).  
- **Remodeling logic:** Immune or stromal activation leads to medial smooth muscle hypertrophy/hyperplasia, perivascular collagen deposition, and reduced compliance—hallmarks of pulmonary vascular remodeling.  
- **Key uncertainty:** Whether MK-derived polyamines reach vascular target cells in sufficient concentration and whether AMD1 activity truly controls polyamine flux in hypoxic MKs (as opposed to alternative SAM-consuming pathways, e.g., methylation).

**Directional chain:**  
1. Hypoxia upregulates methionine import and/or methionine cycle flux in lung-resident MKs.  
2. Elevated methionine feeds SAM, which via AMD1 is partitioned toward polyamine synthesis (spermidine/spermine) rather than methylation.  
3. Candidate downstream axis: **immune‑mediated** (polyamines influence T‑helper/Th17‑like tone, macrophage activation) or **direct vascular‑wall** (polyamines act on SMC/fibroblasts) or **EV/stromal**.  
4. Broad cellular/tissue response: Perivascular inflammation, medial smooth muscle hypertrophy, and adventitial collagen accumulation.  
5. Contribution to remodeling phenotype: Medial thickening, muscularization, vascular stiffness.

**Candidate downstream axes:**  
- Plausible axes: immune-mediated (Th17-like/ macrophage), direct vascular-wall, EV/stromal.  
- Working model (provisional): immune‑mediated – polyamines modify local T‑cell or macrophage programs, amplifying vascular pathology.  
- Specific examples: spermidine, SAM, Th17 cell function, STAT3 activation, IL‑6/IL‑17 family cytokines, α‑SMA+ cell expansion.  
- MK-origin gap: MK polyamine secretion profile, stability, and diffusion in vivo not proven; AMD1 overexpression in MKs not directly measured at protein/activity level.  
- Falsification: MK‑specific Amd1 knockout or pharmacological AMD1 inhibition (e.g., SAM486A) should prevent hypoxia‑induced polyamine accumulation in lung, blunt perivascular immune changes, and reduce medial thickening. If AMD1 blockade fails to alter polyamine levels or vascular remodeling, the direction is falsified.

**Evidence basis:**  
- User-provided data:  
  - Metabolomics: methionine 3.26 log2FC up in MK-PH vs MK-control (*sFig6A Raw data.xlsx*).  
  - Seurat: AMD1 expression pct 31.44% in MKs, MK enrichment 1.353, PH-vs-control MK log2FC 1.77, p=6.55e‑06.  
- Public dataset metadata or analyzed public data: GSE289322 (bulk transcriptomics, case–control) provides a validation opportunity – check whether AMD1 is upregulated in PH lung tissue relative to control. If confirmed, supports tissue-level relevance.  
- Literature: AMD1/mTORC1 axis in polyamine metabolism (PMID 28658205); polyamines and EIF5A hypusination in cancer (PMID 38965534); broader roles in immuno‑metabolism.  
- Biological rationale: Polyamines are known regulators of cell proliferation and immune polarization; SAM/polyamine ratio influences methylation vs. polyamine synthesis.  
- Evidence status: Direct (metabolite change, MK gene expression, and differential expression in user scRNA‑seq); indirect (polyamine‑to‑vascular links from literature); public validation possible.

**Predicted observations:**  
- In MKs: Increased AMD1 protein/enzyme activity, elevated spermidine/spermine, and reduced SAM in PH-MK.  
- In recipient or tissue compartment: Elevated polyamines in PH lung tissue (confirmable by tissue metabolomics), perivascular polyamine-responsive immune signatures (e.g., Th17 markers).  
- In metabolomics or pathway activity: Lung tissue polyamine pathway flux increased; AMD1 inhibition reverses these changes.

**Experimental validation:**  
- Perturbation: MK‑specific Amd1 deletion (Mk-Cre x Amd1 flox) or systemic AMD1 inhibitor (SAM486A) in hypoxia model.  
- Model: Hypoxia‑induced PH mouse (HxSu or chronic hypoxia).  
- Readout: Lung polyamine levels (LC‑MS), perivascular immune cell composition (flow/IF), medial thickness, muscularization metrics, hemodynamics (RVSP, RV hypertrophy).  
- Expected result: Amd1 loss/inhibition blunts polyamine rise, reduces muscularization and stiffness.  
- Falsifying result: No change in lung polyamines or vascular remodeling despite efficient AMD1 blockade.

**Novelty:**  
First direct connection from MK methionine metabolism through AMD1‑polyamine axis to pulmonary vascular remodeling. AMD1 as an MK metabolic vulnerability in PH.

**Weaknesses:**  
Does not pinpoint the exact polyamine‑responsive cell type; relies on pathway logic (polyamine biology) rather than direct measurement of AMD1 product in MK secretome. Public dataset support absent until GSE289322 is queried.

**Revision relative to previous cycle:**  
Not applicable (first cycle).

**Priority estimate:**  
Score each from 1 to 5:  
- Directional specificity: 5 (clear metabolite → enzyme → pathway axis)  
- Data support: 5 (MK-specific metabolomics + scRNA-seq with strong significance)  
- Literature support: 4 (mTORC1/AMD1 papers; polyamine immunomodulation literature)  
- Novelty: 5 (MK-centric AMD1 axis in PH)  
- Testability: 5 (genetic/pharmacologic AMD1 manipulation in mouse PH feasible)  
- Overall generation priority: 5

**Explicit rejection filter:** Passes all checks (MK-specific, hypoxia-dependent, remodeling phenotype, not generic, testable, non-redundant).

---

**Hypothesis ID:** H2

**Hypothesis title:**  
MK Amd2 upregulation under hypoxia augments spermidine/spermine synthesis to cooperate with Amd1, reinforcing polyamine‑dependent vascular remodeling.

**PI instruction addressed:**  
Additional metabolomics‑driven hypothesis using Amd2, the isoform of AMD1, from the same methionine‑SAM‑polyamine pathway. Addresses potential functional redundancy/compensation.

**Core directional hypothesis:**  
Hypoxia‑induced upregulation of Amd2 in a subset of MKs provides a complementary polyamine synthetic capacity that, together with Amd1, elevates spermidine/spermine in the pulmonary niche, promoting perivascular immune activation and medial thickening.

**Direction-level reasoning summary:**  
- **Data anchor:** Methionine up in PH-MK; Amd2 is a methionine salvage/polyamine pathway neighbor gene. Seurat: Amd2 expressed in 4.4% MKs (enrichment log2 0.93), and significantly upregulated in PH-MK (log2FC 2.18, p=0.024).  
- **Biological interpretation:** While Amd2 expression is lower than Amd1, its hypoxia‑induced rise suggests an alternative or cooperative enzyme for SAM decarboxylation, potentially in a specialized MK subpopulation.  
- **MK-linked pathway logic:** Amd2 is a functional homolog of Amd1; both decarboxylate SAM for polyamine synthesis. Co‑upregulation of Amd1 and Amd2 could drive robust polyamine flux.  
- **Candidate downstream axes:** Same as H1: immune‑mediated, direct vascular‑wall, or EV/stromal. Polyamines influence T effector/memory balance and stromal cell proliferation.  
- **Remodelling logic:** Enhanced polyamine output promotes medial muscularization and perivascular matrix changes.  
- **Key uncertainty:** Whether Amd2 protein is active in MKs and its contribution relative to Amd1; low MK expression percentage may limit impact.

**Directional chain:**  
1. Hypoxia induces methionine accumulation and increases SAM availability.  
2. MKs upregulate both Amd1 and Amd2, diverting SAM into polyamine synthesis.  
3. Candidate downstream axis: immune‑mediated (e.g., shaping T‑helper or macrophage phenotypes) or direct vascular‑wall.  
4. Broad cellular response: immune cell recruitment/activation and vascular smooth muscle hypertrophy.  
5. Contribution to remodeling: medial thickening, muscularization.

**Candidate downstream axes:**  
- Plausible axes: immune-mediated, direct vascular-wall, EV/stromal.  
- Working model: Amd2 cooperates with Amd1 to sustain a polyamine‑rich microenvironment that favors inflammatory T‑cell or macrophage programs.  
- Specific examples: spermidine‑driven T‑cell skewing, macrophage M2‑like polarization.  
- MK-origin gap: Amd2 expression in only 5.9% of PH-MK; whether this is a distinct MK subset with unique secretome is unknown.  
- Falsification: Dual inhibition or KO of Amd1 and Amd2 in MKs should yield greater reversal of polyamine levels and remodeling than Amd1 alone. If Amd2 KO shows no additive effect, its role is dispensable.

**Evidence basis:**  
- User-provided data: Methionine up; Amd2 MK expression (pct 4.37%, enrichment 0.93, PH-up log2FC 2.175, p=0.0235).  
- Public dataset metadata/analyzed: GSE289322 could test if AMD2 is differentially expressed in PH lung; if absent, suggests MK‑specific role.  
- Literature: Amd2 gene context in muscle atrophy metabolomics (PMID 40768332), but no direct vascular literature.  
- Biological rationale: Two AMD genes may provide redundancy or fine‑tuning of polyamine synthesis in distinct cellular states.  
- Evidence status: Direct (gene expression differential) but limited by low MK percentage; inferred pathway role.

**Predicted observations:**  
- In MKs: Amd2 protein detectable in a subset of MKs, induced by hypoxia.  
- In tissue: Polyamine levels reduced more by dual Amd1/Amd2 inhibition than single.  
- In metabolomics: Lung spermidine/spermine correlate with combined Amd1+Amd2 expression.

**Experimental validation:**  
- Perturbation: MK-specific Amd2 knockout, dual Amd1/Amd2 knockout.  
- Model: Hypoxia PH mouse.  
- Readout: Lung polyamines, perivascular immune markers, vascular remodelling, hemodynamics.  
- Expected result: Amd2 loss alone mild effect; dual loss strong protection.  
- Falsifying result: Amd2 loss unchanged, dual loss no better than Amd1 alone.

**Novelty:**  
First consideration of Amd2 in MK biology; highlights gene duplication in polyamine pathway.

**Weaknesses:**  
Low basal and MK-specific expression; risk that Amd2 is not functionally relevant at protein level. No direct metabolite product measured.

**Priority estimate:**  
- Directional specificity: 4 (parallel rationale)  
- Data support: 3 (low expression percentage)  
- Literature support: 2 (sparse)  
- Novelty: 4  
- Testability: 4 (feasible with genetic models)  
- Overall generation priority: 3

---

**Hypothesis ID:** H3

**Hypothesis title:**  
MK methionine accumulation may alter DNA methylation via Dnmt3b, reshaping MK transcriptome and secretome to promote a pro‑remodelling phenotype.

**PI instruction addressed:**  
Exploratory metabolomics‑driven hypothesis linking methionine to Dnmt3b (methylation pathway neighbor) and potentially to an epigenetically driven MK state that impacts vascular cells.

**Core directional hypothesis:**  
Hypoxic MKs channel excess methionine into S‑adenosylmethionine (SAM) for DNA methylation via Dnmt3b, inducing a pro‑fibrotic or pro‑inflammatory MK transcriptional programme that affects perivascular fibroblasts and smooth muscle cells.

**Direction-level reasoning summary:**  
- **Data anchor:** Methionine up in PH-MK; Dnmt3b is a cysteine/methionine metabolism pathway neighbor gene, encoding a DNA methyltransferase. Seurat: Dnmt3b expressed in 2.62% MKs (enrichment 0.19), PH-vs-control MK log2FC 1.59 (p=0.212, not significant).  
- **Biological interpretation:** Although MK expression of Dnmt3b is low and not significantly PH-up, the methionine-SAM-methylation axis is a critical fate‑determining mechanism. Even modest epigenetic changes could prime MKs for altered cytokine or growth factor release.  
- **MK-linked pathway logic:** SAM is the universal methyl donor; Dnmt3b uses SAM for de novo DNA methylation. Methionine accumulation may drive hypermethylation at specific loci, silencing anti‑proliferative genes or activating pro‑remodelling factors.  
- **Candidate downstream axes:** Likely **direct vascular-wall** through MK-derived factors (e.g., TGF‑β, PDGF) or **EV/stromal** through altered MK exosome cargo.  
- **Remodelling logic:** Epigenetically modified MKs could secrete more pro‑fibrotic mediators, promoting fibroblast‑to‑myofibroblast transition and medial hypertrophy.  
- **Key uncertainty:** Low and non‑significant MK expression of Dnmt3b; no methylation data in user data. Methionine pool may not directly control Dnmt3b activity if SAM is diverted to polyamines.

**Directional chain:**  
1. Hypoxia raises methionine levels in MKs.  
2. Elevation of SAM pools may enhance Dnmt3b‑mediated DNA methylation in MKs.  
3. Candidate downstream axis: direct vascular‑wall (secreted growth factors/cytokines) or EV/stromal.  
4. Broad tissue response: Perivascular fibroblast activation, smooth muscle hypertrophy.  
5. Remodelling phenotype: Medial thickening, vascular fibrosis.

**Candidate downstream axes:**  
- Plausible axes: direct vascular-wall, EV/stromal, immune-mediated (altering gene expression of chemokines).  
- Working model (provisional): MK epigenetic reprogramming leads to secretion of pro‑fibrotic factors (e.g., TGF‑β1, CTGF).  
- Specific examples: hypermethylation of SOCS or DUSP genes could enhance STAT3 or MAPK signalling, amplifying MK cytokine output.  
- MK-origin gap: Dnmt3b expression and activity in MKs not validated; methylation changes in MKs not measured.  
- Falsification: MK‑specific Dnmt3b knockout or SAM synthesis inhibition (e.g., MAT2A inhibitor) should prevent hypoxia‑induced pro‑remodelling MK secretome. If MK epigenetic profile unchanged and secretion unchanged, hypothesis fails.

**Evidence basis:**  
- User-provided data: Methionine up; Dnmt3b expression low, not significant PH-up.  
- Public dataset metadata: GSE289322 may show DNMT3B expression in lung tissue; if absent, argues against tissue‑level relevance.  
- Literature: Methionine‑SAM‑methylation axis in immune cell differentiation; no vascular‑specific Dnmt3b reports in MKs.  
- Biological rationale: Epigenetic regulation of MK biology is established; Dnmt3b is involved in hematopoietic differentiation.  
- Evidence status: Speculative (metabolite link present, enzyme expression weak, no direct epigenetic data).

**Predicted observations:**  
- In MKs: Increased SAM/SAH ratio, global DNA hypermethylation at specific promoters, altered transcriptome (e.g., upregulated Ccl2, Tgfβ1).  
- In tissue: Pro‑fibrotic cytokine signature around MK‑rich regions.  
- In metabolomics: SAM consumption into methylation pathway.

**Experimental validation:**  
- Perturbation: Dnmt3b inhibitor (e.g., nanaomycin A) or Mk‑specific Dnmt3b knockout; alternatively, manipulate SAM levels with MAT2A inhibitor.  
- Model: Hypoxic PH mouse.  
- Readout: MK DNA methylation (RRBS), MK secretome analysis, perivascular collagen deposition, medial thickness.  
- Expected result: Reduced pro‑fibrotic MK output and attenuated vascular fibrosis.  
- Falsifying result: No change in MK DNA methylation at candidate loci or vascular phenotype.

**Novelty:**  
Links MK methionine metabolism to epigenetic control, a new paradigm in PH.

**Weaknesses:**  
Very weak supporting evidence for Dnmt3b in MKs; the hypothesis is exploratory and may be false.

**Revision relative to previous cycle:**  
Not applicable.

**Priority estimate:**  
- Directional specificity: 4  
- Data support: 1 (no significant MK expression change)  
- Literature support: 2  
- Novelty: 5  
- Testability: 4  
- Overall generation priority: 2 (low, due to weak data support)

---

**Hypothesis ID:** H4

**Hypothesis title:**  
MK-mediated retinoic acid degradation via Cyp26b1 blunts local retinoid signalling, relieving repression of inflammatory pathways and perivascular fibrosis.

**PI instruction addressed:**  
Metabolomics‑driven: retinoic acid (RA) up in PH-MK, path to Cyp26b1 enzyme, MK expression, candidate downstream axis.

**Core directional hypothesis:**  
Hypoxia upregulates Cyp26b1 in MKs to catabolize retinoic acid, reducing local retinoid‑mediated immune regulation or vascular quiescence, thereby permitting perivascular inflammation and medial hypertrophy.

**Direction-level reasoning summary:**  
- **Data anchor:** Retinoic Acid up in PH-MK (log2FC 3.44). Cyp26b1 is a direct compound-enzyme (retinoic acid hydroxylase) in Retinol metabolism. Seurat: Cyp26b1 expressed in 7.86% MKs (enrichment 0.73), PH-vs-control log2FC 0.91 (p=0.253, not significant).  
- **Biological interpretation:** RA is a potent immunomodulator and vascular stabilizer. MK accumulation of RA may reflect increased synthesis or decreased degradation. Cyp26b1 expression trends upward (though non-significant), suggesting MKs may attempt to catabolize excess RA; alternatively, hypoxia could upregulate Cyp26b1 to lower local RA, lifting immune suppression and promoting vascular remodeling.  
- **MK-linked pathway logic:** Cyp26b1 is the key enzyme for RA clearance. If MKs deplete local RA, they could create a pro-inflammatory niche (RA normally restrains Th17 cells and promotes Treg).  
- **Candidate downstream axes:** **Immune‑mediated** (loss of RA‑dependent Treg/Th17 balance, more Th17‑like inflammation) or **direct vascular‑wall** (RA signals directly quench SMC proliferation).  
- **Remodelling logic:** De-repression of inflammatory cascades or loss of anti‑proliferative signals in smooth muscle leads to medial thickening.  
- **Key uncertainty:** Low MK Cyp26b1 expression and borderline significance; RA levels may not reflect functional activity; Cyp26b1 may be induced in other cells, not MKs.

**Directional chain:**  
1. Hypoxia increases RA synthesis or impairs its degradation globally; MKs upregulate Cyp26b1 as a compensatory response, but insufficient, leading to net RA accumulation. Alternatively, MK Cyp26b1 may actively degrade RA.  
2. MK metabolic state: RA accumulation or RA degradation in MKs could alter MK function (e.g., autocrine effects) or local microenvironment.  
3. Candidate downstream axis: immune‑mediated (shift from Treg to Th17), direct vascular‑wall.  
4. Broad cellular response: Perivascular T cell infiltration, SMC proliferation.  
5. Remodelling phenotype: Muscularization, perivascular fibrosis.

**Candidate downstream axes:**  
- Plausible axes: immune-mediated (T helper balance), direct vascular-wall, unresolved.  
- Working model: MK Cyp26b1 reduces local RA, disinhibiting Th17‑like responses that drive vascular remodeling.  
- Specific examples: RA, IL‑17, IL‑6.  
- MK-origin gap: It is not certain that RA or RA‑degrading activity emanates from MKs; local RA may be produced by other lung cells.  
- Falsification: MK‑specific Cyp26b1 overexpression or knockout should alter lung RA levels and Th17/Treg balance, and impact vascular remodeling. No effect would negate the MK‑centric hypothesis.

**Evidence basis:**  
- User-provided data: RA up in PH-MK; Cyp26b1 MK pct 7.86%, PH‑up trend not significant.  
- Public dataset metadata: GSE289322 can probe CYP26B1 expression in PH vs control lung.  
- Literature: Retinoic acid pathway in vascular biology and immune regulation; Cyp26b1 in retinoid homeostasis.  
- Biological rationale: RA is known to inhibit smooth muscle proliferation and modulate immunity; its depletion could be pro‑remodelling.  
- Evidence status: Inferred/weak (metabolite up, enzyme trend, no direct evidence of activity or functional consequence).

**Predicted observations:**  
- In MKs: Cyp26b1 enzymatic activity increased; reduced RA in MK-conditioned medium.  
- In tissue: Lower RA in perivascular regions, increased Th17 markers (RORγt, IL‑17).  
- In metabolomics: Lower RA in lung tissue of PH mice relative to control, and RA supplementation ameliorates remodeling.

**Experimental validation:**  
- Perturbation: MK-specific Cyp26b1‑KO or pharmacological Cyp26 inhibitor (e.g., talarozole).  
- Model: Hypoxic PH.  
- Readout: Lung RA levels, perivascular T‑cell profiling, medial thickness.  
- Expected result: Cyp26b1 loss raises local RA, decreases Th17 cells, reduces remodeling.  
- Falsifying result: No change in lung RA or remodeling after MK‑specific CYP26b1 deletion.

**Novelty:**  
First MK‑specific retinoid metabolism hypothesis in pulmonary hypertension.

**Weaknesses:**  
Weak MK‑expression evidence; RA measurement in MKs could be contamination; Cyp26b1 function in MKs not demonstrated.

**Priority estimate:**  
- Directional specificity: 4  
- Data support: 2 (trend only)  
- Literature support: 3  
- Novelty: 5  
- Testability: 4  
- Overall generation priority: 2

---

**Self-filtered rejected ideas:**  
- **Methionine → Mat2a:** Although Mat2a is a direct enzyme for SAM synthesis, its MK expression was low (pct 8.73%, enrichment -0.29) and not PH-up (log2FC 0.56, p=0.1). No mechanism-ready shortlist entry. Rejected for weak MK-specific PH differential and redundancy with AMD1-focused hypotheses.  
- **Tryptophan → Ido1:** Ido1 is a pathway neighbor for tryptophan metabolism (shortlist excluded it). Seurat: MK pct 3.06% with negative enrichment (-0.83) and non-significant PH change. Tryptophan up (log2FC 2.51) in PH-MK could support an IDO‑driven kynurenine pathway, but Ido1 is not meaningfully expressed in MKs; thus not MK-specific.  
- **Lactate → Ldha:** Ldha is a direct enzyme (glycolysis) with strong MK expression (76% MK pct) and PH-up (p=6.2e‑07). However, the shortlist did not include it because lactate was not in the 30 selected metabolites? Actually, lactate appears in the complete evidence chains, but not in the mechanism-ready shortlist (maybe missing differential MK metabolite from sFig6A). The provided metabolomics file for MKs does not list lactate. So no direct MK metabolite differential for lactate available. Rejected due to missing MK-specific metabolite measurement.  
- **Glutathione-related metabolites:** Many rows showed weak MK enrichment or no PH signal; rejected due to lack of positive MK shift.  
- **Inosine → Pnp/Nt5c2:** Inosine was up (log2FC 3.82) and Pnp showed MK pct 20.31% but negative MK enrichment (-1.22) and PH-up (p=3.81e‑06). However, Pnp is not MK-enriched relative to other cells, and the purine degradation axis lacks a clear vascular remodeling link; the mechanism cues were generic “purine metabolism.” Rejected because directionality toward vascular remodeling unclear and no MK-specific metabolite-enzyme correlation beyond expression.  
- **Hyaluronan or ECM metabolites:** no direct enzyme with MK-specific expression in the provided lists.

**Requests for Tool Use Agent:**  
- Check the public dataset GSE289322 for differential expression of Amd1, Amd2, Dnmt3b, Cyp26b1, Pnp, Nt5c2 in PH vs control lung tissue. Report log2FC and p-values to strengthen or refute these hypotheses.  
- Search PubMed for: “AMD1 AND vascular smooth muscle”, “polyamines AND pulmonary hypertension”, “Cyp26b1 AND lung inflammation”, “DNA methylation AND megakaryocyte”.
